{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T21:57:14Z","timestamp":1771883834827,"version":"3.50.1"},"reference-count":13,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"vor","delay-in-days":730,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006501","name":"Cystic Fibrosis Foundation Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jcf.2020.08.003","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T08:30:49Z","timestamp":1597221049000},"page":"395-396","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5436-9722","authenticated-orcid":false,"given":"Jennifer L.","family":"Taylor-Cousar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2407-7374","authenticated-orcid":false,"given":"Raksha","family":"Jain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3916-8260","authenticated-orcid":false,"given":"Tracy M.","family":"Kazmerski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moira L.","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0025-2422","authenticated-orcid":false,"given":"Natalie E.","family":"West","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter G.","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward F.","family":"Nash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.jcf.2020.08.003_bib0001","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jcf.2020.08.003_bib0002","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1164\/rccm.200705-664OC","article-title":"Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health","volume":"176","author":"Flume","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2020.08.003_bib0003","unstructured":"Azithromycin USPI."},{"key":"10.1016\/j.jcf.2020.08.003_bib0004","doi-asserted-by":"crossref","first-page":"m331","DOI":"10.1136\/bmj.m331","article-title":"Associations between macrolide antibiotics prescribing during pregnancy and adverse child outcomes in the UK: population based cohort study","volume":"368","author":"Fan","year":"2020","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jcf.2020.08.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2019.06.050","article-title":"In utero exposure to antibiotics and risk of congenital malformations: a population-based study","volume":"221","author":"Damkier","year":"2019","journal-title":"Am J Obstet Gynecol"},{"issue":"12","key":"10.1016\/j.jcf.2020.08.003_bib0006","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1002\/pds.3900","article-title":"Use of macrolides during pregnancy and the risk of birth defects: a population-based study","volume":"24","author":"Berard","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"10.1016\/j.jcf.2020.08.003_bib0007","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s40264-019-00884-5","article-title":"Prenatal exposure to macrolides and risk of congenital malformations: a meta-analysis","volume":"43","author":"Mallah","year":"2020","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.jcf.2020.08.003_bib0008","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3109\/14767058.2016.1161747","article-title":"Maternal co-morbidities and neonatal outcomes associated with cystic fibrosis","volume":"30","author":"Jelin","year":"2017","journal-title":"J Matern Fetal Neonatal Med"},{"key":"10.1016\/j.jcf.2020.08.003_bib0009","unstructured":"Registry CFFP2018Annual Data Report Bethesda, Maryland [Available from: https:\/\/www.cff.org\/Research\/Researcher-Resources\/Patient-Registry\/2018-Patient-Registry-Annual-Data-Report.pdf."},{"issue":"2","key":"10.1016\/j.jcf.2020.08.003_bib0010","doi-asserted-by":"crossref","first-page":"1901208","DOI":"10.1183\/13993003.01208-2019","article-title":"ERS\/TSANZ Task Force Statement on the management of reproduction and pregnancy in women with airways diseases","volume":"55","author":"Middleton","year":"2020","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.jcf.2020.08.003_bib0011","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1164\/rccm.201906-1206OC","article-title":"Pulmonary outcomes associated with long-term azithromycin therapy in cystic fibrosis","volume":"201","author":"Nichols","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.jcf.2020.08.003_bib0012","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1128\/AAC.02011-12","article-title":"Blood, tissue, and intracellular concentrations of azithromycin during and after end of therapy","volume":"57","author":"Matzneller","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.jcf.2020.08.003_bib0013","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/01.ftd.0000195617.69721.a5","article-title":"Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis","volume":"28","author":"Wilms","year":"2006","journal-title":"Ther Drug Monit"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199320308183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:44:34Z","timestamp":1761601474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199320308183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":13,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,5]]}},"alternative-id":["S1569199320308183"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2020.08.003","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Concerns regarding the safety of azithromycin in pregnancy - relevance for women with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2020.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}